Lenalidomide with Low- or High-Dose Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma (MM)


Lenalidomide with Low- or High-Dose Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma (MM)
Slides from a presentation at ASH 2010 and transcribed comments from a recent interview
with Rafael Fonseca, MD (12/22/10)

Vesole DH et al. Lenalidomide plus low-dose dexamethasone (Ld): Superior one and two year survival regardless of age compared to lenalidomide plus high-dose dexamethasone (LD). Proc ASH 2010;Abstract 308.

Dr Fonseca is Professor of Medicine at the Mayo Clinic Arizona and Deputy Director of the Mayo Clinic Cancer Center in Scottsdale, Arizona.